Improvements in PANSS scores following OL PP1M were similar in recent RIS/PALI (mean ) and no prior RIS/PALI (-21.1 [16.40]) subgroups at OL endpoint. Relapse-free rates during DB phase were comparable across recent RIS/PALI (PP3M: 89.7%; PP1M: 87.1%, 95% CI for difference: [-4.7; 10.0]) and no RIS/PALI subgroups (PP3M: 91.6%; PP1M: 90.8%, 95% CI for difference: [-4.5; 6.0] : PP1M or PP3M), TTO and TTR, and descriptively compared. TTO and TTR were further analyzed by final OL dose (50/75 mg eq., 100 mg eq. and 150 mg eq.) and age (18-25, 26-50 and 50+ years) subgroups. Results: Overall incidence of EPS-related AEs was 12.6% (PP1M) during OL phase, reducing to 8.3% (PP3M) and 7.4% (PP1M) during DB phase. Median TTO for all EPS-related AEs was 17 days (range: 1-120) after PP1M OL treatment; 115 days (range: 1-323) and 98.5 days (range: 1-322) after treatment with PP3M and PP1M, respectively (DB phase). Median TTR was 36.5 days (range: 1-127) in PP1M group (OL), and was generally similar for PP3M (91 days [range: 1-336]) vs. PP1M (85.5 days [range: 1-337]) during DB phase. Overall median TTO and TTR values were comparable between PP3M and PP1M formulations. Subgroup analysis revealed no clear dose-response or age-related differences in TTO and TTR of EPS-events for the two formulations. Discussion: The overall incidence of EPS-related AEs, TTO and TTR of EPS-events were found to be comparable in patients with schizophrenia receiving either PP3M or PP1M long-acting injectable.
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Methods: Post hoc analysis of a randomized, double-blind (DB), parallel-group, multicenter, noninferiority study (NCT01515423). Subjects with schizophrenia were treated with PP once-monthly (PP1M) in a 17-week open-label (OL) phase. Upon meeting clinical stabilization criteria, they were randomized 1:1 to PP1M or PP once-every-3-months (PP3M) in a 48-week relapse-prevention phase. Subjects were evaluated based on duration of illness (≤5, 6-10, and >10 years since diagnosis); PP1M and PP3M results were combined. Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) scale scores and functional remission rates (PSP >70 from week 13 [OL] and during DB phase for ≥6 months) were analyzed. No adjustment was made for multiplicity. Results: 532, 337, and 558 subjects diagnosed with schizophrenia ≤5, 6-10, and >10 years ago, respectively, entered OL phase. Of these, 379 (71.2%), 235 (69.7%), and 380 (68.1%) met clinical stabilization criteria and entered DB phase. Significant differences were observed in the ≤5 and 6-10 groups versus the >10 group from DB baseline to DB endpoint for PANSS and PSP total scores (P<0.03 for all). More patients achieved functional remission in the ≤5 (26.4%) and 6-10 (30.2%) groups versus the >10 group (18.6%). Conclusion: Improvements were observed with PP LAIs in all subgroups, with greater improvements among patients earlier in the illness (<5 or 5-10 years) compared to those with more chronic illness (>10 years). Support: Janssen Scientific Affairs, LLC
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Emergence of Tardive Dyskinesia upon Clozapine Treatment: A Case Report
